Related Experiment Video
Updated: May 14, 2026

Rodent Inferior Vena Cava Venoplasty Balloon Model
Published on: May 24, 2024
[Antithrombotic therapy for polyvascular atherosclerosis]
Insights
Patients with polyvascular atherosclerosis face double the cardiovascular event risk. Intensified anticoagulation offers greater benefit for these patients, despite a similar bleeding risk compared to monovascular cases.
Area of Science:
- Cardiovascular Medicine
- Vascular Biology
- Pharmacology
Abstract:
Patients with polyvascular atherosclerosis are twice as likely to have cardiovascular events as patients with monovascular atherosclerosis. Anticoagulant therapy improves the prognosis and is therefore clearly recommended. Intensified anticoagulation is more effective in reducing risk but is associated with a higher risk of bleeding. Compared to patients with monovascular atherosclerosis, patients with polyvascular atherosclerosis benefit more, as the absolute risk of ischemic events is higher - with the same risk of bleeding.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Atherosclerosis III: Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis IV: Nursing Management